AXS-07 – New Combination Drug for Migraine in the Pipeline
Axsome Therapeutics has a new combination abortive drug in the pipeline. At the moment it’s going by the name AXS-07.
Every new medication attempts to solve one or more problems. This one is focused on two – well, maybe three – different things. First, fast absorption. The medication needs to get into your system at full power as soon as possible.
Second, it needs to keep working long enough to really make a difference. And when we say “working”, that brings us to a third thing – alleviation of symptoms.
This medication is a combination of two medications. First, rizatriptan, an already well-known abortive drug that targets migraine specifically. The second is meloxicam, which is a type of NSAID, specifically a COX-2 NSAID. That would put meloxicam in the same class as Celebrex (celecoxib), which may be a little more familiar to you.
Axsome is using a special formulation of meloxicam (“MoSEIC™ meloxicam “) that is designed to get into your system faster and last longer. Since both of these medications attack migraine in different ways, they have the potential to attack different symptoms in a more complete way.
That’s what the developers hope. There are two trials that are starting, if you’re interested in being a party of the development of AXS-07. Both are in the USA, and all the contact information is here:
- Maximizing Outcomes in Treating Acute Migraine (MOMENTUM)
- Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine
For more information, see Axsome’s site: AXS-07